151 related articles for article (PubMed ID: 27764842)
1. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
; Blinman P; Mileshkin L; Khaw P; Goss G; Johnson C; Capp A; Brooks S; Wain G; Kolodziej I; Veillard AS; O'Connell R; Creutzberg CL; Stockler MR
Br J Cancer; 2016 Nov; 115(10):1179-1185. PubMed ID: 27764842
[TBL] [Abstract][Full Text] [Related]
2. Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?
Blinman P; Hughes B; Crombie C; Christmas T; Hudson M; Veillard AS; Muljadi N; Millward M; Wright G; Flynn P; Windsor M; Stockler M; McLachlan SA;
Eur J Cancer; 2015 Aug; 51(12):1529-37. PubMed ID: 26059196
[TBL] [Abstract][Full Text] [Related]
3. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
Post CCB; Mens JWM; Haverkort MAD; Koppe F; Jürgenliemk-Schulz IM; Snyers A; Roeloffzen EMA; Schaake EE; Slot A; Stam TC; Beukema JC; van den Berg HA; Lutgens LCHW; Nijman HW; de Kroon CD; Kroep JR; Stiggelbout AM; Creutzberg CL
Gynecol Oncol; 2021 Jun; 161(3):727-733. PubMed ID: 33712276
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?
Blinman P; Duric V; Nowak AK; Beale P; Clarke S; Briscoe K; Boyce A; Goldstein D; Hudson M; Stockler M
Eur J Cancer; 2010 Jul; 46(10):1800-7. PubMed ID: 20137908
[TBL] [Abstract][Full Text] [Related]
5. Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Heritier S; Boyle F; Beith J; Wilcken NR; Coates AS; Simes RJ; Stockler MR
Patient Educ Couns; 2008 Aug; 72(2):239-45. PubMed ID: 18434070
[TBL] [Abstract][Full Text] [Related]
6. Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.
Blinman P; Martin A; Jefford M; Goldstein D; Boadle D; Morris M; Tebbutt N; Aiken C; Harkin A; Segelov E; Haydon A; Iveson T; Stockler MR
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 34159294
[TBL] [Abstract][Full Text] [Related]
7. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
Duric VM; Stockler MR; Heritier S; Boyle F; Beith J; Sullivan A; Wilcken N; Coates AS; Simes RJ
Ann Oncol; 2005 Nov; 16(11):1786-94. PubMed ID: 16126738
[TBL] [Abstract][Full Text] [Related]
8. Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?
Blinman PL; Davis ID; Martin A; Troon S; Sengupta S; Hovey E; Coskinas X; Kaplan R; Ritchie A; Meade A; Eisen T; Stockler MR
Ann Oncol; 2018 Feb; 29(2):370-376. PubMed ID: 29177440
[TBL] [Abstract][Full Text] [Related]
9. Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer.
Moth E; McLachlan SA; Veillard AS; Muljadi N; Hudson M; Stockler MR; Blinman P
Lung Cancer; 2016 May; 95():8-14. PubMed ID: 27040845
[TBL] [Abstract][Full Text] [Related]
10. Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Boyle F; Beith J; Wilcken NR; Heritier S; Coates AS; John Simes R; Stockler MR
Psychooncology; 2007 Jan; 16(1):48-59. PubMed ID: 16856128
[TBL] [Abstract][Full Text] [Related]
11. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.
Duric V; Stockler M
Lancet Oncol; 2001 Nov; 2(11):691-7. PubMed ID: 11902540
[TBL] [Abstract][Full Text] [Related]
12. What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.
Lawrence NJ; Martin A; Davis ID; Troon S; Sengupta S; Hovey E; Coskinas X; Kaplan R; Smith B; Ritchie A; Meade A; Eisen T; Blinman P; Stockler MR
Kidney Cancer; 2018 Aug; 2(2):123-131. PubMed ID: 30740581
[TBL] [Abstract][Full Text] [Related]
13. Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.
Niikura N; Kimura M; Iwamoto T; Hayashi N; Shintoku J; Saito Y; Suzuki Y; Tokuda Y
Breast Cancer; 2013 Jan; 20(1):67-74. PubMed ID: 22109640
[TBL] [Abstract][Full Text] [Related]
14. Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
Duric VM; Fallowfield LJ; Saunders C; Houghton J; Coates AS; Stockler MR
Br J Cancer; 2005 Dec; 93(12):1319-23. PubMed ID: 16333242
[TBL] [Abstract][Full Text] [Related]
15. Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review.
Hamelinck VC; Bastiaannet E; Pieterse AH; Jannink I; van de Velde CJ; Liefers GJ; Stiggelbout AM
Cancer Treat Rev; 2014 Sep; 40(8):1005-18. PubMed ID: 24986544
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
Montagna E; Pagan E; Bagnardi V; Colleoni M; Cancello G; Munzone E; Dellapasqua S; Bianco N; Campennì G; Iorfida M; Mazza M; De Maio A; Veronesi P; Sangalli C; Scateni B; Pettini G; Pravettoni G; Mazzocco K; Galimberti V
Breast Cancer Res Treat; 2020 Dec; 184(3):783-795. PubMed ID: 32929568
[TBL] [Abstract][Full Text] [Related]
17. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
18. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review.
Blinman P; Alam M; Duric V; McLachlan SA; Stockler MR
Lung Cancer; 2010 Aug; 69(2):141-7. PubMed ID: 20570009
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.
Hamelinck VC; Bastiaannet E; Pieterse AH; de Glas NA; Portielje JE; Merkus JW; den Hoed ID; van de Velde CJ; Liefers GJ; Stiggelbout AM
Clin Breast Cancer; 2016 Oct; 16(5):379-388. PubMed ID: 27212474
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile?
Blinman P; McLachlan SA; Nowak AK; Duric VM; Brown C; Wright G; Millward M; Fong K; Stockler MR
Lung Cancer; 2011 May; 72(2):213-8. PubMed ID: 20817340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
